Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a sell rating to a hold rating in a report released on Thursday morning, ValuEngine reports.

INO has been the topic of several other reports. Piper Jaffray Companies lowered their price objective on Inovio Pharmaceuticals from $12.00 to $10.00 and set an overweight rating on the stock in a research report on Wednesday, July 17th. BidaskClub downgraded Inovio Pharmaceuticals from a sell rating to a strong sell rating in a research report on Saturday, June 1st. HC Wainwright reiterated a buy rating and issued a $13.00 target price on shares of Inovio Pharmaceuticals in a research report on Tuesday, June 11th. Maxim Group reiterated a buy rating and issued a $8.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, Zacks Investment Research downgraded Inovio Pharmaceuticals from a buy rating to a hold rating and set a $3.50 target price on the stock. in a research report on Tuesday, May 28th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. Inovio Pharmaceuticals currently has an average rating of Buy and an average price target of $7.69.

Shares of Inovio Pharmaceuticals stock traded up $0.03 during trading hours on Thursday, hitting $2.69. The company’s stock had a trading volume of 630,725 shares, compared to its average volume of 620,530. The stock has a 50 day moving average price of $2.80. Inovio Pharmaceuticals has a 12-month low of $2.15 and a 12-month high of $6.30. The firm has a market cap of $260.76 million, a P/E ratio of -2.56 and a beta of 2.03. The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 1.02.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.01). Inovio Pharmaceuticals had a negative net margin of 295.24% and a negative return on equity of 97.95%. The business had revenue of $2.83 million during the quarter, compared to analysts’ expectations of $4.44 million. As a group, analysts predict that Inovio Pharmaceuticals will post -0.95 EPS for the current year.

In other Inovio Pharmaceuticals news, CEO Jong Joseph Kim sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $3.31, for a total transaction of $331,000.00. Following the sale, the chief executive officer now directly owns 2,411,055 shares of the company’s stock, valued at $7,980,592.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David B. Weiner sold 16,352 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $2.72, for a total value of $44,477.44. Following the sale, the director now directly owns 797,110 shares in the company, valued at $2,168,139.20. The disclosure for this sale can be found here. Insiders have sold 2,882,673 shares of company stock worth $7,099,911 over the last three months. 7.90% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in shares of Inovio Pharmaceuticals during the first quarter valued at approximately $40,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Inovio Pharmaceuticals in the second quarter worth approximately $40,000. Amalgamated Bank bought a new position in Inovio Pharmaceuticals in the fourth quarter worth approximately $50,000. Stoneridge Investment Partners LLC bought a new position in Inovio Pharmaceuticals in the second quarter worth approximately $50,000. Finally, Creative Planning bought a new position in Inovio Pharmaceuticals in the second quarter worth approximately $50,000. 50.76% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Read More: What does an equal weight rating mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.